Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Reboxetine · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 3 | EXPERIMENTAL | - |
| 4 | SHAM_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| [S,S]-Reboxetine | DRUG | 10 mg oral tablet once a day dosing |
| Placebo | DRUG | 0 mg oral tablet once a day dosing |
Inclusion Criteria: * Male or female of any race, at least 18 years of age * Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites) Exclusion Criteria: * Patients with other severe pain (e...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Axsome Therapeutics, Inc. | AXSM | 1 | PHASE3 | AXS-14 |
| Grace Therapeutics, Inc. | GRCE | 1 | - | Undisclosed |
Reboxetine is an investigational small molecule being studied for the treatment of fibromyalgia, pain, and major depressive disorder. It is being developed by Pfizer, Inc. (NYSE: PFE). The drug has completed clinical trials in these indications, including a Phase 3 study in fibromyalgia.
Reboxetine is a selective norepinephrine reuptake inhibitor, meaning it works by blocking the reuptake of norepinephrine in the brain, which increases its levels. This mechanism is thought to help modulate pain pathways and improve mood, which is why it is being studied for pain conditions and depression.
Reboxetine is being developed by Pfizer, Inc., a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer has conducted multiple clinical trials of Reboxetine for pain-related conditions and fibromyalgia.
Reboxetine has completed Phase 3 clinical development for fibromyalgia, with a large study involving 1,129 patients. It has also completed Phase 2 trials for pain conditions. However, it is not FDA approved and remains an investigational drug, as no approval status has been reported.
Reboxetine has been studied in several completed trials, including NCT00143442 for postherpetic neuralgia, NCT00288652 for pain, NCT00357825 for fibromyalgia, and NCT00612170, a Phase 3 study in fibromyalgia. All trials are completed, with no active trials currently listed.
Yes, Reboxetine is also known as [S,S]-Reboxetine, which is the specific enantiomer used in the clinical trials. The trials listed under NCT numbers refer to [S,S]-Reboxetine, and this form is the one being investigated for pain and fibromyalgia indications.